Search results for "Risk factor"

showing 10 items of 4321 documents

Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.

2016

Multiple sclerosis (MS) is a prevalent neurological disease of complex etiology. Here, we describe the characterization of a multi-incident MS family that nominated a rare missense variant (p.G420D) in plasminogen (PLG) as a putative genetic risk factor for MS. Genotyping of PLG p.G420D (rs139071351) in 2160 MS patients, and 886 controls from Canada, identified 10 additional probands, two sporadic patients and one control with the variant. Segregation in families harboring the rs139071351 variant, identified p.G420D in 26 out of 30 family members diagnosed with MS, 14 unaffected parents, and 12 out of 30 family members not diagnosed with disease. Despite considerably reduced penetrance, lin…

0301 basic medicineProbandMaleGene ExpressionQH426-470multiple sclerosis0302 clinical medicineRisk FactorsGenotypeMissense mutationExomegeneticsguidelinesGenetics (clinical)degradationriskGeneticsLinkagedeficiencyMiddle AgedPenetrance3. Good healthPedigreeplasminogenChromosomes Human Pair 6FemalelinkageAdultGenotype610 Medicine & healthInvestigationsBiologysystemPolymorphism Single Nucleotideblood-brain-barrieractivatorMultiple sclerosisAssociation03 medical and health scienceslamininGenetic linkagemedicineGeneticsHumansAmino Acid Sequenceddc:610Molecular BiologyGenotypingAgeddiseaseSequence Homology Amino AcidMultiple sclerosisCase-control studyassociationPlasminogenmedicine.diseasediagnostic-criteria030104 developmental biologyCase-Control StudiesImmunologySequence Alignment030217 neurology & neurosurgery
researchProduct

Is proteomics of value in cardiovascular risk assessment?

2019

Purpose of review To briefly summarize recently published evidence in the field of cardiovascular proteomics, focusing on its ability to improve cardiovascular risk stratification and critically discussing still open and burning issues and future perspectives of proteomics research. Recent findings Several epidemiological studies have demonstrated an improvement in cardiovascular risk prediction beyond traditional risk factors by adding novel biomarkers, identified by both discovery and targeted proteomics. However, only a moderate improvement in risk discrimination over clinical variables was observed. Moreover, despite different outcomes there was also a strong overlap of identified candi…

0301 basic medicineProteomicsClinical variablesGrowth Differentiation Factor 15Endocrinology Diabetes and MetabolismDisease030204 cardiovascular system & hematologyProteomicsBioinformaticsRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsGeneticsMedicineAnimalsHumansBiomarker discoveryNatriuretic PeptidesMolecular BiologyNutrition and Dieteticsbusiness.industryInterleukinsCell BiologyTargeted proteomics030104 developmental biologyC-Reactive ProteinCardiovascular DiseasesRisk stratificationMetalloproteasesCardiology and Cardiovascular MedicinebusinessRisk assessmentBiomarkersCurrent opinion in lipidology
researchProduct

The microbiome in respiratory medicine: current challenges and future perspectives

2017

The healthy lung has previously been considered to be a sterile organ because standard microbiological culture techniques consistently yield negative results. However, culture-independent techniques report that large numbers of microorganisms coexist in the lung. There are many unknown aspects in the field, but available reports show that the lower respiratory tract microbiota: 1) is similar in healthy subjects to the oropharyngeal microbiota and dominated by members of the Firmicutes, Bacteroidetes and Proteobacteria phyla; 2) shows changes in smokers and well-defined differences in chronic respiratory diseases, although the temporal and spatial kinetics of these changes are only partially…

0301 basic medicinePulmonary and Respiratory MedicineCystic FibrosisRespiratory SystemDiseaseBiologyCystic fibrosisMicePulmonary Disease Chronic Obstructive03 medical and health sciencesIdiopathic pulmonary fibrosis0302 clinical medicineRisk FactorsTerminology as TopicProteobacteriaPulmonary MedicinemedicineAnimalsHumansIdiopathic Interstitial PneumoniasMicrobiomeLung11 Medical and Health SciencesBronchiectasisLungBacteroidetesMicrobiotamedicine.diseasebiology.organism_classificationBronchiectasis030104 developmental biologymedicine.anatomical_structure030228 respiratory systemHost-Pathogen InteractionsImmunologyDysbiosisProteobacteriaDysbiosisEuropean Respiratory Journal
researchProduct

Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.

2017

1.1. Cardiovascular disease and dyslipidemia: prevalence and global economic impact Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, reaching 31% of deaths in 2012 [1]. In particular, atherosclerosis and ischemic heart disease (IHD) are the main causes of premature death in Europe and are responsible for 42% of deaths in women and 38% in men under 75 years old [2]. The global economic impact of CVD is estimated to have been US $906 billion in 2015 and is expected to rise by 22% by 2030 [3]. Cardiovascular diseases also represent the major cause of disability in developed countries. It has been estimated that their growing burden could lead to a global increase in…

0301 basic medicineRED YEAST RICEDiseasePharmacologyPLACEBO-CONTROLLED TRIALchemistry.chemical_compound0302 clinical medicineCARDIOVASCULAR RISK-FACTORSFamily historyhealth care economics and organizationseducation.field_of_studyCONJUGATED LINOLEIC-ACIDOrvostudományokGeneral MedicinehumanitiesC-REACTIVE PROTEIN3. Good healthDENSITY-LIPOPROTEIN CHOLESTEROL030220 oncology & carcinogenesislipids (amino acids peptides and proteins)nutraceuticalLife Sciences & Biomedicineposition paperMODERATELY HYPERCHOLESTEROLEMIC SUBJECTSmedicine.medical_specialtyRANDOMIZED CONTROLLED-TRIALSeducationPopulationGuidelines/RecommendationsKlinikai orvostudományok03 medical and health sciencesMedicine General & InternallipidGeneral & Internal MedicineInternal medicineDiabetes mellitusmedicineCORONARY-HEART-DISEASERisk factoreducationFATTY LIVER-DISEASEScience & TechnologyCholesterolbusiness.industrydyslipidemia1103 Clinical Sciencesmedicine.disease030104 developmental biologychemistryrecommendationsEtiologybusinessDyslipidemiaArchives of medical science : AMS
researchProduct

Noncoding RNAs in Critical Limb Ischemia

2020

Peripheral artery disease, caused by chronic arterial occlusion of the lower extremities, affects over 200 million people worldwide. Peripheral artery disease can progress into critical limb ischemia (CLI), its more severe manifestation, which is associated with higher risk of limb amputation and cardiovascular death. Aiming to improve tissue perfusion, therapeutic angiogenesis held promise to improve ischemic limbs using delivery of growth factors but has not successfully translated into benefits for patients. Moreover, accumulating studies suggest that impaired downstream signaling of these growth factors (or angiogenic resistance) may significantly contribute to CLI, particularly under h…

0301 basic medicineRNA UntranslatedAngiogenesisCritical IllnessNeovascularization PhysiologicDisease030204 cardiovascular system & hematologyBioinformaticsArticlePeripheral Arterial Disease03 medical and health sciences0302 clinical medicineIschemiaRisk FactorsmicroRNADiabetes MellitusAnimalsHumansMedicineTherapeutic angiogenesisProgenitor cellHypoxiaInflammationbusiness.industryStem CellsHemodynamicsCritical limb ischemiaHypoxia (medical)Prognosisbody regions030104 developmental biologyGene Expression RegulationRegional Blood FlowArteriogenesismedicine.symptomCardiology and Cardiovascular MedicinebusinessSignal TransductionArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy.

2020

Abstract Background and aims Polyvascular disease (PVD) affects approximately 20% of patients with atherosclerosis and is a strong independent risk factor for ischemic outcomes. However, guidelines do not address screening or treatment for PVD, and there have been no PVD-specific trials. We reviewed subgroup analyses of large randomized controlled trials of more intense antithrombotic therapy to determine whether increased intensity of therapy improved ischemic outcomes in patients with PVD. Methods MEDLINE, MEDLINE in-Process, EMBASE, and the Cochrane Library were queried for randomized controlled trials larger than 5000 patients evaluating secondary prevention therapies in patients with c…

0301 basic medicineRelative risk reductionmedicine.medical_specialtyPopulationCoronary Artery Disease030204 cardiovascular system & hematologyCochrane Librarylaw.invention03 medical and health sciencesPeripheral Arterial Disease0302 clinical medicineRandomized controlled trialFibrinolytic AgentslawRisk FactorsInternal medicineAntithromboticmedicineHumansRisk factoreducationeducation.field_of_studybusiness.industryAbsolute risk reductionAtherosclerosis030104 developmental biologyRelative riskCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsAtherosclerosis
researchProduct

Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?

2018

Anti-PCSK9 (proprotein convertase subtilisin kexin 9) monoclonal antibodies (Mab) are novel, potent lipid-lowering drugs. They demonstrated to improve the lipid profile in high cardiovascular risk patients. Anti-PCSK9 Mab inhibit the targeted low-density lipoprotein (LDL)-receptor degradation induced by PCSK9 protein and are able to reduce LDL cholesterol (LDL-C) levels on top of conventional lipid-lowering therapy. Though these drugs proved to be very safe in the short-term, little is known about the possible long-term effects, due to the short period of their marketing. The genetic low cholesterol syndromes (LCS) represent the natural models of the lipid-lowering anti-PCSK9 therapy, and a…

0301 basic medicineSerine Proteinase InhibitorsTime FactorsPhysiologymedicine.drug_class030204 cardiovascular system & hematologyPharmacologyMonoclonal antibodyRisk Assessment03 medical and health sciencesPCSK9 Genechemistry.chemical_compound0302 clinical medicineRisk FactorsPhysiology (medical)Diabetes mellitusmedicineAnimalsHumansDyslipidemiasmedicine.diagnostic_testbusiness.industryCholesterolPCSK9Anticholesteremic AgentsPCSK9 InhibitorsAntibodies MonoclonalCholesterol LDLmedicine.diseaseFatty LiverHypocholesterolemia030104 developmental biologyTreatment OutcomechemistryDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicineLipid profilebusinessCognition DisordersBiomarkersLipoproteinCardiovascular research
researchProduct

Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension

2021

: The COVID-19 infection has rapidly spread around the world and a second wave is sweeping in many countries. Different clinical and epidemiological aspects characterize the disease and their understanding is necessary to better face the management of the pandemic in progress. The Italian society of arterial hypertension with the SARS-RAS study has contributed significantly to the knowledge of the interaction between inhibition of the renin-angiotensin system and COVID-19 infection. Furthermore, the study results help to understand some of the main aspects related to mortality and morbidity deriving from the infection through a multicentre analysis throughout the national territory.

0301 basic medicineSettore MED/09 - Medicina InternaCross-sectional studyDiseaseComorbiditySeverity of Illness IndexComorbiditiesRenin-Angiotensin System0302 clinical medicineRisk FactorsSex-differences.EpidemiologyPandemicFrailtySars-Cov2Treatment OutcomeItalyAnti-hypertensive therapy; comorbidities; frailty; Sars-Cov2; sex-differencesHypertensionComorbiditiePosition PaperRisk assessmentCardiology and Cardiovascular Medicinemedicine.medical_specialtySex-differenceRisk Assessment03 medical and health sciencesPharmacotherapySex FactorsSeverity of illnessmedicineAnti-hypertensive therapy Sars-Cov2 Frailty Comorbidities Sex-differencesInternal MedicineHumansArterial PressureAnti-hypertensive therapy Comorbidities Frailty Sars-Cov2 Sex-differencesIntensive care medicineAnti-hypertensive therapyAntihypertensive AgentsAnti-hypertensive therapy; Comorbidities; Frailty; Sars-Cov2; Sex-differences; Antihypertensive Agents; Arterial Pressure; COVID-19; Comorbidity; Cross-Sectional Studies; Frailty; Humans; Hypertension; Italy; Renin-Angiotensin System; Risk Assessment; Risk Factors; Severity of Illness Index; Sex Factors; Treatment OutcomeSettore MED/14 - Nefrologiabusiness.industryCOVID-19medicine.diseaseComorbiditySex-differences030104 developmental biologyCross-Sectional Studiesbusiness030217 neurology & neurosurgery
researchProduct

Genetic 3’UTR variation is associated with human pigmentation characteristics and sensitivity to sunlight

2017

Sunlight exposure induces signalling pathways leading to the activation of melanin synthesis and tanning response. MicroRNAs (miRNAs) can regulate the expression of genes involved in pigmentation pathways by binding to the complementary sequence in their 3'untranslated regions (3'UTRs). Therefore, 3'UTR SNPs are predicted to modify the ability of miRNAs to target genes, resulting in differential gene expression. In this study, we investigated the role in pigmentation and sun-sensitivity traits, as well as in melanoma susceptibility, of 38 different 3'UTR SNPs from 38 pigmentation-related genes. A total of 869 individuals of Spanish origin (526 melanoma cases and 343 controls) were analysed.…

0301 basic medicineSkin NeoplasmsSNPSingle-nucleotide polymorphismSkin PigmentationDermatologyBiologyBiochemistryPolymorphism Single NucleotideWhite People03 medical and health sciencesGene FrequencyRisk FactorsWnt3A ProteinmicroRNAGene expressionGenotypeSNPHumansGenetic Predisposition to DiseasePhotosensitivity DisordersRNA MessengerHair ColorNaevusMolecular BiologyGene3' Untranslated RegionsMelanomaSolar lentiginesAdaptor Proteins Signal TransducingGeneticsLentigoBinding SitesEye ColorThree prime untranslated regionMicroRNAProtective Factors3' untranslated regionPhenotypeMicroRNAs030104 developmental biologyPhenotypeSpainCase-Control Studies
researchProduct

Stagewise pseudo-value regression for time-varying effects on the cumulative incidence

2015

In a competing risks setting, the cumulative incidence of an event of interest describes the absolute risk for this event as a function of time. For regression analysis, one can either choose to model all competing events by separate cause-specific hazard models or directly model the association between covariates and the cumulative incidence of one of the events. With a suitable link function, direct regression models allow for a straightforward interpretation of covariate effects on the cumulative incidence. In practice, where data can be right-censored, these regression models are implemented using a pseudo-value approach. For a grid of time points, the possibly unobserved binary event s…

0301 basic medicineStatistics and ProbabilityCarcinoma HepatocellularTime FactorsEpidemiologyComputer scienceFeature selectionBiostatistics01 natural sciences010104 statistics & probability03 medical and health sciencesRisk FactorsStatisticsCovariateEconometricsHumansComputer SimulationCumulative incidenceRegistries0101 mathematicsEvent (probability theory)Models StatisticalIncidenceLiver NeoplasmsAbsolute risk reductionRegression analysisRegression030104 developmental biologyRegression AnalysisJackknife resamplingAlgorithmsStatistics in Medicine
researchProduct